BioAge Labs, Inc. BIOA
BioAge Labs, Inc. (Nasdaq: BIOA) is a cardio-renal-metabolic drug developer. Its lead program, BGE-102, is in Phase 2 for Diabetic Macular Edema (DME) and Cardiovascular Risk. Its next catalyst on record is BGE-102 (QUELL-CV): Topline data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BGE-102 (QUELL-CV) — Topline data (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BGE-102 | Diabetic Macular Edema (DME) | small molecule | Phase 2 |
| BGE-102 | Cardiovascular risk (QUELL-CV) | small molecule | Phase 2 |
| APJ agonist programs (injectable and oral) | Obesity | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026completed enrollment QUELL-CV Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated inflammation completed enrollment of approximately 160 participants.
QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 dose-ranging trial evaluating three once-daily oral doses of BGE-102 (30 mg, 60 mg, and 90 mg) against placebo in adults with obesity and elevated baseline inflammation, has completed enrollment of approximately 160 participants.
Filing - Oct 2, 2026started First participant dosed in QUELL-DME, a randomized three-arm Phase 2 trial (~180 participants) of oral BGE-102 alone or with anti-VEGF in DME; primary endpoint BCVA change at week 12.
BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“DME”), and provided updates on the QUELL-DME Phase 2 tri
Filing - started BioAge dosed first participant in QUELL-DME, a Phase 2 trial of BGE-102 in diabetic macular edema in September 2026.
In September 2026, BioAge announced that the first participant was dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.